A first-in-human trial of chimeric antigen receptor T-cell therapy in men with advanced prostate cancer showed promising results with minimal adverse effects. Researchers at City of Hope treated 14 men with metastatic castration-resistant prostate cancer using CAR T-cell therapy targeting prostate stem-cell antigen. While four patients experienced reductions in PSA levels, the therapy showed limited persistence of CAR T cells beyond 28 days. Despite some instances of cytokine release syndrome, the therapy was generally well-tolerated. Further research is planned to optimize efficacy by preparing the tumor microenvironment for CAR T-cell therapy.
Source link
Trial of CAR-T for prostate cancer takes steps toward ‘potentially curative’ therapy
